|
Loại |
Nguồn |
| 3 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 59 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 84 |
Tạp chí |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Tạp chí |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 289 |
Tạp chí |
Jim LK.
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Ann Pharmacotherapy 1993 ; 27: 704-707. |
| 299 |
Tạp chí |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 335 |
Tạp chí |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 367 |
Tạp chí |
Thompson DF, Allen LV, Desai SR, Rao PS.
Compatibility of furosemide with aminoglycoside admixtures.
Am J Hosp Pharm 1985 ; 42: 116-119. |
| 421 |
Tạp chí |
Foley PT, Bosso JA, Bair JN, Townsend RJ.
Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures.
Am J Hosp Pharm 1985 ; 42: 839-843. |
| 492 |
Tạp chí |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 905 |
Tạp chí |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 958 |
Tạp chí |
Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M.
Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion.
Ann Pharmacotherapy 1990 ; 24: 440-442. |
| 999 |
Tạp chí |
Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224. |
| 1022 |
Tạp chí |
Hutchinson SMW.
Heparin and aminoglycosides instability.
Drug Intell Clin Pharm 1986 ; 20: 886. |
| 1035 |
Tạp chí |
Bisaillon S, Sarrazin R.
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
J Parenter Sci Technol 1983 ; 37: 129-132. |
| 1200 |
Tạp chí |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742. |
| 1236 |
Tạp chí |
Kuhn RJ, Nahata MC.
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.
Am J Hosp Pharm 1986 ; 43: 1241-1242. |
| 1410 |
Tạp chí |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Tạp chí |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Tạp chí |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1754 |
Tạp chí |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1925 |
Tạp chí |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1929 |
Tạp chí |
Rigge DC, Jones MF.
Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes.
J Pharm Biomed Anal 2004 ; 35: 1251-1256. |
| 2296 |
Thông tin của nhà sản xuất |
Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017 |
| 3522 |
Thông tin của nhà sản xuất |
Flucloxacillin - Summary of Product Characteristics.
Actavis 2013 |
| 3523 |
Thông tin của nhà sản xuất |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018 |
| 3526 |
Thông tin của nhà sản xuất |
Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010 |
| 3527 |
Thông tin của nhà sản xuất |
Amoxicillin (Amoxil®) – Summary of Product Characteristics
Glaxo Smith Kline 2018 |
| 3540 |
Thông tin của nhà sản xuất |
Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010 |
| 3543 |
Thông tin của nhà sản xuất |
Ceftazidime – Summary of Product Characteristics
Wockhardt 2013 |
| 3544 |
Thông tin của nhà sản xuất |
Cefoperazone (Cefobid®) - Summary of Product Characteristics
Pfizer 2006 |
| 3545 |
Thông tin của nhà sản xuất |
Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009 |
| 3546 |
Thông tin của nhà sản xuất |
Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007 |
| 3548 |
Thông tin của nhà sản xuất |
Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007 |
| 3578 |
Thông tin của nhà sản xuất |
Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011 |
| 3586 |
Thông tin của nhà sản xuất |
Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
Actavis France 2010 |
| 3587 |
Thông tin của nhà sản xuất |
Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
GlaxoSmithKline 2014 |
| 3594 |
Thông tin của nhà sản xuất |
Metronidazole (Flagyl®) - Summary of Product Characteristics
Zentiva 2013 |
| 3644 |
Thông tin của nhà sản xuất |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3656 |
Thông tin của nhà sản xuất |
Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2014 |
| 3674 |
Thông tin của nhà sản xuất |
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016 |
| 3687 |
Thông tin của nhà sản xuất |
Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013 |
| 3883 |
Thông tin của nhà sản xuất |
Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016 |
